New: Hepatitis Timeline: http://goo.gl/83sp9J
New: Fabry TImeline:
High Level Timelines of privileges regarding the commercialization and use of knowledge
Draft
This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors.
Timeline of privileged regarding the commercialization and use of knowledge
Continue Reading →
USPTO’s $4 million of Congressionally Mandated Spending on intellectual property initiatives, for fy 2009
This is the USPTO list of grants for fy 2009. The $4 million in grants were used to influence global norms on IPR policy.
A new round of grants will go out soon for fy 2010, involving another $4 million of Congressionally Mandated Spending on Intellectual Property Initiatives (IPI).
Continue Reading →
Introduction
Part 1 of our notes on the August 25, 2010 version of the ACTA consolidated text, covering pages 1-9 of the text, are available here. These notes cover the remainder of August 25, 2010 ACTA text, from pages 10 to 29.
Continue Reading →
KEI has obtained a copy of the August 25, 2010 version of the ACTA consolidated negotiating text. This is Part 1 of our initial notes on the document.
(Part 2 is available here.)
(revised September 9, 2010)
Preamble
The preamble in the August, 25, 2010 text includes 10 paragraphs, of which only 3 do not have brackets.
Continue Reading →
European Commission (DG 1) note on the WHO’s Revised Drug Stategy
EUROPEAN COMMISSION
DIRECTORATE GENERAL 1
EXTERNAL RELATIONS: COMMERCIAL POLICY AND RELATIONS WITH NORTH AMERICA. THE
FAR EAST, AUSTRALIA AND NEW ZEALAND
Directorate D -Sectoral trade questions, market access
New technologies, Intellectual property, public procurement
Brussels, 5 October 1998
1/D/3/BW D (98)
Continue Reading →
A pdf copy of the resolution is attached to this page.
THE FIFTY-SECOND WORLD HEALTH ASSEMBLY
WHA52.19
Agenda Item 13
May 24, 1999
Revised Drug Strategy
The Fifty-second World Health Assembly,
Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy[1];
Continue Reading →
CONFIDENTIAL RELEASED IN FULL
CONFIDENTIAL PTQ1906
PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00
425261 271705Z /38 O 271615Z MAY 98
FM USMISSION GENEVA
TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON
AMEMBASSY BRASILIA
AMEMBASSY BUENOS AIRES AMEMBASSY PRETORIA AMEMBASSY HARARE
AMEMBASSY LILONGWE AMEMBASSY LUSAKA
AMEMBASSY WINDHOEK AMEMBASSY BERN
AMEMBASSY CANBERRA
AMEMBASSY STOCKHOLM AMEMBASSY TOKYO AMEMBASSY OSLO
AMEMBASSY BRUSSELS AMEMBASSY BONN
AMEMBASSY OTTAWA AMEMBASSY CAIRO CDC ATLANTA
Continue Reading →
A copy of this document is available here:
http://dsp-psd.pwgsc.gc.ca/Collection-R/LoPBdP/BP/prb9946-e.htm
RB 99-46E
PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA – CHRONOLOGY OF SIGNIFICANT EVENTS
Prepared by:
Margaret Smith
Law and Government Division
30 March 2000
PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA – CHRONOLOGY OF SIGNIFICANT EVENTS
Continue Reading →
Draft
This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors.
Timeline of privileged regarding the commercialization and use of knowledge
Continue Reading →